title: [The expression of CD19 in 210 cases of childhood acute leukemia and its significance].
abstract: OBJECTIVE
  To investigate the expression of CD19 on childhood acute leukemia (AL) and its significance, and to provide evidence for the diagnosis and differential diagnosis as well as monoclonal antibody-targeting treatment of leukemia.
  
  
  METHODS
  There were 210 cases of childhood AL, of which 130 cases were male and 80 were female with a mean age of 9 years old. Using a panel of 27 fluorochrome directly labeled monoclonal antibodies, 210 samples from the patients were analyzed with CD45/SSC double parameters and multi-color flow cytometry to determine the expression of CD19.
  
  
  RESULTS
  In the 93 cases of B lineage acute lymphoblastic leukemia (ALL), the positive rate (98.9%, 92/93) of CD19 was significantly higher than that of the other B cell related antigens, such as CD10 (88.2%, 82/93, P = 0.003), CD20 (24.7%, 23/93, P = 0.001) and CD22 (60.2%, 56/93, P = 0.001). CD19 was expressed on all 8 cases of B/myeloid (My) hybrid acute leukemia (HAL) and 1 case of B/T HAL, but was not expressed on all 24 cases of T lineage leukemia and 5 cases of T/My HAL. In the 79 cases of acute myeloid leukemia (AML), only 5 (6.3%) cases expressed CD19. The positive rate (6.3%) of CD19 on AML was significantly lower than that on B lineage ALL (98.9%, P = 0.001). The percentage of CD19 positive cells in B/My HAL (41.6% - 88.7% with a mean of 73.8%) was significant higher than that in CD19(+)-AML (21.4% - 50.4% with a mean of 24.2%; Run Sum test, P = 0.0084). Of the 210 cases, 102 were B lineage related AL including B lineage ALL, B/My HAL and B/T HAL. In B lineage related AL, the sensitivity and the specificity of CD19 was 99.0% (101/102) and 95.4% (13/108) while the positive predictive and the negative predictive values to B lineage were 95.3% (101/106) and 99.0% (103/104), respectively. Using CD19(+) as a single reagent to diagnose B lineage, the false positive rate was 4.6% (5/108) and the false negative rate was 1.0% (1/102) with a general diagnosis index (GDI) of 94.4% [GDI = 1-(false positive rate + false negative rate)].
  
  
  CONCLUSIONS
  CD19 is continuously and stably expressed on all stages of B lineage differentiation. It is a reliable cell membrane marker for diagnosing B lineage ALL and an ideal target for antibody-targeting treatment of leukemia as well; the expression degree of CD19 can be used to distinguish B/My HAL from CD19(+)-AML; CD19 didn't express on normal myeloid cells but did on some AML cells. Therefore it can be used to detect the minimal residual disease.
authors.affiliation: Children's Hospital, Medical School of Zhejiang University, Hangzhou 310003, China.
authors.forename: Ying-hu
authors.initials: YH
authors.lastname: Chen
authors.forename: Yong-min
authors.initials: YM
authors.lastname: Tang
authors.forename: Hong-qiang
authors.initials: HQ
authors.lastname: Shen
authors.forename: Hua
authors.initials: H
authors.lastname: Song
authors.forename: Shi-long
authors.initials: SL
authors.lastname: Yang
authors.forename: Shu-wen
authors.initials: SW
authors.lastname: Shi
authors.forename: Bai-qin
authors.initials: BQ
authors.lastname: Qian
authors.forename: Wei-qun
authors.initials: WQ
authors.lastname: Xu
authors.forename: Bo-tao
authors.initials: BT
authors.lastname: Ning
mesh_terms: D000293:Adolescent; D018941:Antigens, CD19 / Q000032:analysis*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007223:Infant; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000145:classification / Q000276:immunology*
chemical_list: D018941:Antigens, CD19